Auna S.A. Class A (AUNA)
NYSE:AUNA
Want to see AUNA full AI Analyst Report?
Top Page
Auna S.A. Class A
(NYSE:AUNA)
Select Model
Select Model
Rating:57Neutral
Price Target:
$5.00
▲(0.20% Upside)
Action:ReiteratedDate:04/01/26
The score is held back primarily by high leverage and recent softness/volatility in profitability and cash generation, despite a multi-year turnaround. Support comes from attractive valuation (low P/E) and a constructive earnings-call outlook including refinancing and 2026 growth guidance, while technicals are mildly positive but not yet strong on a long-term basis.
Positive Factors
Free cash flow improvement
Auna's materially higher free cash flow and larger cash balance strengthen operating liquidity and reduce short-term funding pressure. Durable FCF improvement provides capacity to fund capex, service debt and invest in higher-margin lines (oncology, clinics), supporting execution over the next 2–6 months.
Negative Factors
High leverage and debt-heavy balance sheet
Sustained high gross debt and elevated leverage limit strategic flexibility and increase sensitivity to margin or cash-flow setbacks. Even after refinancing leverage sits above targeted levels, meaning interest and principal servicing remain a structural constraint on investments and downside resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow improvement
Auna's materially higher free cash flow and larger cash balance strengthen operating liquidity and reduce short-term funding pressure. Durable FCF improvement provides capacity to fund capex, service debt and invest in higher-margin lines (oncology, clinics), supporting execution over the next 2–6 months.
Read all positive factors
Auna S.A. Class A (AUNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$366.36M
Dividend YieldN/A
Average Volume (3M)446.37K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth5.41%
EPS Growth-103.36%
CountryUS
Employees14,605
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.12
Shares Outstanding30,095,388
10 Day Avg. Volume235,431
30 Day Avg. Volume446,366
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.31
Price to Sales (P/S)0.12
P/FCF Ratio3.08
Enterprise Value/Market Cap12.67
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda5.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.17
Revenue Forecast (FY)$4.71B
Auna S.A. Class A Business Overview & Revenue Model
Company Description
Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in L...
How the Company Makes Money
Auna makes money primarily by providing healthcare services to patients through its hospitals and outpatient/ambulatory clinics. Its revenue is mainly generated from (1) inpatient care, including admissions, surgeries, procedures, room/bed days, i...
Auna S.A. Class A Earnings Call Summary
Earnings Call Date:Mar 10, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 27, 2026
Earnings Call Sentiment Positive
The call presents a constructive financial and operational reset: the company strengthened liquidity and capital structure through a sizable refinancing, delivered strong free cash flow and a marked increase in adjusted net income, and highlighted robust, scalable performance in Peru alongside early signs of stabilization and targeted growth initiatives in Mexico (notably oncology and new commercial wins). However, near-term profitability was pressured by a decline in consolidated EBITDA and margin compression driven largely by Mexico underperformance and one-off/extraordinary refinancing costs, as well as receivable impairments and payor-related risk management in Colombia. Management provided confident 2026 guidance (12% revenue and EBITDA growth) and outlined clear mitigation levers, indicating the positives outweigh the transitory challenges.Positive Updates
Consolidated Revenue Growth
Consolidated revenue grew 6% FX-neutral in Q4 2025 and 4% for the full year 2025, driven by strong performance in Peru (+11% in the quarter) and Colombia (+6% in the quarter).
Negative Updates
Decline in Adjusted EBITDA and Margin Compression
Consolidated adjusted EBITDA declined 14% FX-neutral in Q4 2025 to PEN 220 million with margin contracting 4.5 percentage points to 19.5%. For the full year, adjusted EBITDA fell 3% FX-neutral to PEN 917 million and margin decreased ~1.7 percentage points to just under 21%.
Read all updates
Q4-2025 Updates
Positive
Negative
Consolidated Revenue Growth
Consolidated revenue grew 6% FX-neutral in Q4 2025 and 4% for the full year 2025, driven by strong performance in Peru (+11% in the quarter) and Colombia (+6% in the quarter).
Read all positive updates
Company Guidance
Auna guided to FX‑neutral adjusted EBITDA growth of 12% in 2026 and revenue growth of 12%, with CapEx at approximately 4% of revenue, supported by disciplined cost management, a Mexico recovery and ongoing strategic investments; this follows Q4’25 adjusted EBITDA of PEN 220m (19.5% margin, -4.5 pp YoY) and FY’25 adjusted EBITDA of PEN 917m (-3% FX‑neutral, margin just under 21%, -1.7 pp), Q4 adjusted net income of PEN 136m (FY adjusted net income PEN 336m), and builds on an $825m refinancing that cut blended funding costs by over 100 bps from ~12.5%, reduced interest paid (PEN 454m, or PEN 407m net of refinancing fees), and supports continued deleveraging toward a 3.0x net debt/EBITDA target from the current ~3.6x while leveraging stronger cash generation (free cash flow PEN 582m, +35%; year‑end cash PEN 335m, +42%).Auna S.A. Class A Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
42
Neutral
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.13B | 4.40B | 3.85B | 2.44B | 1.97B |
| Gross Profit | 1.57B | 1.64B | 1.33B | 836.88M | 682.26M |
| EBITDA | 758.40M | 928.12M | 723.50M | 301.35M | 175.09M |
| Net Income | 92.01M | 110.72M | -252.04M | -85.24M | -27.09M |
Balance Sheet | |||||
| Total Assets | 7.30B | 7.08B | 7.69B | 6.59B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 365.65M | 335.97M | 334.26M | 208.69M | 138.77M |
| Total Debt | 3.66B | 3.77B | 3.92B | 3.51B | 1.49B |
| Total Liabilities | 5.53B | 5.46B | 5.91B | 5.04B | 2.28B |
| Stockholders Equity | 1.60B | 1.48B | 1.47B | 1.06B | 495.82M |
Cash Flow | |||||
| Free Cash Flow | 161.76M | 577.64M | 417.25M | 10.67M | -106.03M |
| Operating Cash Flow | 242.83M | 668.50M | 582.41M | 162.64M | 183.34M |
| Investing Cash Flow | -78.83M | -236.82M | -173.15M | -3.21B | -291.99M |
| Financing Cash Flow | -74.31M | -418.12M | -370.00M | 3.13B | -102.13M |
Auna S.A. Class A Technical Analysis
Neutral
4.99
Price Trends
5.32
Positive
5.07
Positive
5.63
Negative
Market Momentum
0.07
Positive
51.43
Neutral
30.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUNA, the sentiment is Neutral. The current price of 4.99 is below the 20-day moving average (MA) of 5.71, below the 50-day MA of 5.32, and below the 200-day MA of 5.63, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.43 is Neutral, neither overbought nor oversold. The STOCH value of 30.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AUNA.
Auna S.A. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $871.07M | 32.08 | 6.89% | ― | 22.00% | 589.71% | |
57 Neutral | $366.36M | -1.96 | 6.04% | ― | 5.41% | -103.36% | |
54 Neutral | $333.21M | -0.79 | -24.30% | ― | -21.56% | -577.69% | |
53 Neutral | $1.77B | -4.96 | -80.84% | ― | 25.24% | -3915.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $242.68M | 23.32 | -13.79% | ― | -15.82% | -34.41% | |
45 Neutral | $401.61M | -0.16 | 5.89% | ― | -2.87% | ― |
* Healthcare Sector Average
AUNA
Auna S.A. Class A
4.95
-2.05
-29.29%
SNDA
Sonida Senior Living
37.15
13.19
55.05%
CYH
Community Health
2.87
-0.41
-12.50%
CCRN
Cross Country Healthcare
10.11
-3.73
-26.95%
TALK
Talkspace
5.20
2.16
71.05%
AIRS
Airsculpt Technologies
3.44
0.88
34.37%
Auna S.A. Class A Corporate Events
Auna Files 2025 Form 20‑F, Boosting Transparency for Latin American Healthcare Platform
Apr 22, 2026
Auna S.A. is a Latin American healthcare company operating in Mexico, Peru and Colombia, focused on prevention and complex diseases that drive the highest healthcare spending. Founded in 1989, it has built a large integrated platform of hospitals,...
Auna S.A. Publishes Preliminary Q1 2026 Operating Metrics for Latin American Healthcare Platform
Apr 17, 2026
On April 17, 2026, Auna S.A. released preliminary key performance indicators for the quarter ended March 31, 2026, detailing volumes across its Mexican, Peruvian, and Colombian operations. The disclosure, which the company plans to repeat each qua...
Auna S.A. Posts Strong FY25 Cash Generation and Sets 2026 Growth Targets Amid Mexico Recovery
Mar 10, 2026
On March 10, 2026, Auna reported its fourth-quarter and full-year 2025 results, showing flat reported revenue for the year at S/4,385 million but a 35% jump in free cash flow and a sharp rise in adjusted net income to S/336 million. Adjusted EBITD...
Auna and EsSalud Clear Path to Build Peru’s Largest Outpatient Facility in Lima
Feb 26, 2026
On February 26, 2026, Auna S.A. announced it has executed an addendum to its public-private partnership agreement with Peru’s social health insurer EsSalud, clearing the way to begin construction of Torre Trecca in Lima, a 23‑story, hi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.